Funds Try To Revive Sanofi Obesity Drug Securities Suit
Two retirement funds have asked a federal judge to reopen a securities fraud class action alleging Sanofi-Aventis made misrepresentations regarding the side effects of an anti-obesity drug while it was awaiting...To view the full article, register now.
Already a subscriber? Click here to view full article